Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT.
This participation provides an opportunity for Helus Pharma to highlight its pipeline of proprietary NSAs (novel serotonergic agonists), which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need in mental health conditions such as depression, anxiety, and other disorders. Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder.
The company's approach is centered on providing durable improvements in mental health through its proprietary NSAs. With a research portfolio that includes investigational compounds, Helus Pharma is positioned to potentially transform the treatment landscape for mental health conditions. The fireside chat at the H.C. Wainwright conference will allow the company to discuss its clinical data, development plans, and the broader implications of its work.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's website at www.helus.com or follow the team on social media. The full press release is available at https://ibn.fm/KsnJW.
